GlassScriptPhysician profile
Patience Jurkiewicz
NPI 1477298354
$7,800.40
in general payments reported to CMS, 2019-2025
19 companies · $2,988 in 2025
The $2,988 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,120 · 2024: $2,693 · 2025: $2,988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,067 · Travel and Lodging: $2,680 · Education: $54.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,066.90 |
| Travel and Lodging | $2,679.50 |
| Education | $54.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,254.10 | 2023-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Medtronic, INC. | $1,089.99 | 2023-2024 | Synchromedii, Intellis Adaptivestim |
| Abbvie INC. | $759.84 | 2023-2025 | |
| Abbott Laboratories | $752.45 | 2023-2025 | Eterna, Proclaim |
| Pfizer INC. | $536.64 | 2023-2025 | |
| Tersera Therapeutics LLC | $253.36 | 2023-2025 | Prialt |
| Saluda Medical Americas, INC. | $195.31 | 2025 | Evoke |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.41 | 2023-2025 | Relistor |
| Idorsia Pharmaceuticals US INC | $150.72 | 2023-2024 | Quviviq |
| Averitas Pharma INC. | $118.91 | 2024 | Qutenza |
| Lundbeck LLC | $117.82 | 2024-2025 | Vyepti |
| Collegium Pharmaceutical, INC. | $94.34 | 2023-2025 | Xtampza, Belbuca |
| Merz Pharmaceuticals, LLC | $79.76 | 2025 | Xeomin |
| Vertex Pharmaceuticals Incorporated | $49.77 | 2024-2025 | |
| Bioventus LLC | $37.60 | 2024-2025 | Durolane, Xcell |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $37.60 | 2023-2024 | Senza |
| Ibsa Pharma INC. | $37.28 | 2024-2025 | Licart, Tirosint, Flector |
| Tonix Medicines, INC. | $27.41 | 2025 | Tonmya |
| Scilex Pharmaceuticals INC. | $20.09 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patience Jurkiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.